论文部分内容阅读
B细胞淋巴瘤（BCL）是一类具有明显异质性的恶性肿瘤。近年来，随着诊疗模式的不断改进，BCL患者的缓解率有所提高，但部分患者仍然会出现复发难治的现象。嵌合抗原受体T细胞（CAR-T）是一种新疗法，目前CD19 CAR-T已被批准用于复发难治弥漫大B细胞淋巴瘤的治疗。第62届美国血液学会年会上，多项研究报道了CAR-T治疗复发难治BCL的最新进展。“,”B-cell lymphoma (BCL) is a highly heterogeneous malignant tumor. In recent years, although the remission rate of BCL patients has been improved with the improvement of diagnosis and treatment methods, some patients still relapse and become refractory. Chimeric antigen receptor T cells (CAR-T) is a novel therapy. At present, CD19 CAR-T has been approved for the treatment of relapsed/refractory diffuse large B-cell lymphoma. At the 62nd American Society of Hematology Annual Meeting, a number of studies reported the latest progress of CAR-T in the treatment of relapsed/refractory BCL.